Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor by Andreani, Cristina et al.
www.aging-us.com 508 AGING (Albany NY) 
 
INTRODUCTION 
 
Several natural compounds have recently gathered 
renewed interest as potential anti-tumor agents. 
Resveratrol (trans -3,4’,5-trihydroxystilbene), a natural 
polyphenol found in grapes, peanuts, cocoa, berries, and 
red wine, has been described as a putative cancer 
chemo-preventive compound able to counteract breast 
cancer initiation, promotion and progression [1]. 
Although several in vitro studies have proposed 
resveratrol to exert an anti-tumor activity by inducing 
apoptosis and/or cell cycle arrest in various mammary 
cancer cell lines [2-4], investigations attempting to 
dissect the in vivo effects of resveratrol upon cancer 
onset and progression have led to contradictory results 
[5-7]. Such a controversial scenario can be explained  
 
recalling that resveratrol, as a phytoestrogen, possesses 
both estrogenic and anti-estrogenic activities on ERα-
positive breast cancer [8-10]. The devised experimental 
conditions -dose, timing, way of administration- 
influence the outcome of resveratrol-based studies as 
well [11]. Moreover, the experimental model taken into 
consideration is determinant: the majority of available 
data has been obtained using transplantable or 
carcinogen-inducible tumor models that, even if infor-
mative, fail to reproduce the complexity of spontaneous 
tumorigenesis [11]. To our knowledge, the solely in 
vivo study on a spontaneous mammary tumor model 
was reported by Provinciali et al. who claimed how 
resveratrol supplementation delays tumor onset, growth 
and metastases in HER2/neu transgenic female mice 
[12]. This research was performed in vivo on transgenic 
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ABSTRACT 
 
The phytoestrogen resveratrol has been reported to possess cancer chemo-preventive activity on the basis of
its effects on tumor cell lines and xenograft or carcinogen-inducible in vivo models. Here we investigated the
effects of resveratrol on spontaneous mammary carcinogenesis using Δ16HER2 mice as HER2+/ERα+ breast
cancer model. Instead of inhibiting tumor growth, resveratrol treatment (0.0001% in drinking water; daily
intake of 4μg/mouse) shortened tumor latency and enhanced tumor multiplicity in Δ16HER2 mice. This in vivo
tumor-promoting effect of resveratrol was associated with up-regulation of Δ16HER2 and down-regulation of
ERα protein levels and was recapitulated in vitro by murine (CAM6) and human (BT474) tumor cell lines. Our
results demonstrate that resveratrol, acting as a proteasome inhibitor, leads to Δ16HER2 accumulation which
favors the formation of Δ16HER2/HER3 heterodimers. The consequential activation of downstream
mTORC1/p70S6K/4EBP1 pathway triggers cancer growth and proliferation. This study provides evidence that
resveratrol mechanism of action (and hence its effects) depends on the intrinsic molecular properties of the
cancer model under investigation, exerting a tumor-promoting effect in luminal B breast cancer subtype
models. 
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mice carrying the rat HER2/neu oncogene under the 
transcriptional control of MMTV promoter, and in vitro 
on human SKBR3 cell line, both models representing 
ER-negative (-) and HER2-positive (+) breast cancers 
[13]. They ascribed such protective effects to a decrease 
in HER2 gene expression and a promotion of in situ 
apoptosis observed inside mammary tumor tissues [12].  
 
Even though HER2 over-expression is considered a 
hallmark of aggressive breast cancer subtypes, 
increasing evidence has pointed toward a major 
contribution of Δ16HER2 splice variant (lacking exon-
16), which is commonly co-expressed with wild-type 
HER2, in promoting cancer progression, metastasis and 
resistance to Trastuzumab [14, 15]. The relevance of 
Δ16HER2 and the availability of Δ16HER2 mice, 
transgenic for the human Δ16HER2 oncogenic isoform, 
drove us to evaluate the effects of resveratrol intake on 
Δ16HER2-driven mammary carcinogenesis [16]. 
Unexpectedly, we found resveratrol to promote 
Δ16HER2 carcinogenesis by up-regulating Δ16HER2  
protein levels in both primary tumors and metastases 
and down-regulating ERα expression in tumors, thus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
recapitulating endocrine therapy resistance. 
Mechanistically, resveratrol partially inhibits 
proteasome activity and leads to Δ16HER2 protein 
accumulation. Increased Δ16HER2 levels, in turn, 
trigger the formation of Δ16HER2/HER3 heterodimers 
and the consequent HER3 phosphorylation. The 
resulting activation of mTORC1/p70S6K pathway 
finally fuels cell proliferation and mammary tumor 
development in Δ16HER2 mice.  
 
RESULTS 
 
Resveratrol supplementation promotes 
mammary tumor development in Δ16HER2 mice 
 
In Δ16HER2 mice, the MMTV-driven expression of 
only five copies of the human Δ16HER2 transgene 
triggers neoplastic transformation of mammary 
epithelial cells with a short latency time. Since all 
transgenic females develop multiple asynchronous 
mammary tumors on average at the 15th week of age, 
resveratrol treatment started when the animals were 8 
week-old and proceeded up to 23 weeks of age (Figure  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Resveratrol fuels mammary tumor formation in a luminal B breast cancer in vivo model. (a) Schematic
representation of the experimental workflow used for the treatment of Δ16HER2 mice with vehicle or resveratrol. (b) Kaplan-Meier
disease-free survival plot for vehicle- (n= 9) and resveratrol-treated (n= 9) Δ16HER2 mice. **p ≤ 0.01, Log Rank test. (c) Tumor
multiplicity in resveratrol-treated vs control mice; the number of palpable mammary tumors per mouse is represented as mean ± SD.
Statistical significance was assessed by two-way ANOVA test. (d) Left panel: Representative Hematoxyilin-Eosin (H&E) and PCNA stained
sections of tumors from resveratrol and vehicle treated mice. Magnification 400 X. Right panel: Quantification of PCNA staining in
tumors from resveratrol and vehicle treated mice. Data are expressed as mean ± SEM. *p < 0.05; unpaired two-tailed student t test.  
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1a). As shown in Figure 1b, resveratrol-receiving mice 
displayed a significantly anticipated tumor onset 
developing the first tumor mass at only 9 weeks of age  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(p=0.0099), while the first tumor appeared at 12 weeks 
of age in untreated females. In particular, 50% of 
resveratrol-treated mice presented at least one mammary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Resveratrol treatment induces HER2 over-expression and ERα down-regulation in HER2+/ERα+
mammary carcinomas. (a) Representative western blot analysis of ERα and β-actin (loading control) in spontaneous mammary
tumors from Δ16HER2 mice supplemented or not with resveratrol (left panel), and relative densitometry quantification from
three independent experiments (right panel). The significance was determined by unpaired two-tailed student t test, *p < 0.05.
(b) Representative western blot analysis of HER2 and β-actin (loading control) in spontaneous mammary tumors from Δ16HER2
mice, supplemented or not with resveratrol (left panel), and relative densitometry quantification from three independent
experiments (right panel). The significance was determined by unpaired two-tailed student t test, *p < 0.05. (c) Left panel:
representative immunofluorescence images of tumor sections from control and resveratrol supplemented mice stained with an
antibody anti-HER2 (green) and DRAQ5 dye (red) for nuclei staining. Magnification 400 X. Right panel: quantification of HER2
staining in tumors from resveratrol and vehicle treated mice. Data are expressed as mean ± SEM. *p < 0.05; unpaired two-tailed
student t test. (d) Resveratrol treatment induces HER2 over-expression in lung metastases. Left panel: representative
immunofluorescence images of lung metastasis sections from control and resveratrol supplemented mice stained with an
antibody anti-HER2 (green) and DRAQ5 (red). Magnification 400 X. Right panel: quantification of HER2 staining in tumors from
resveratrol and vehicle treated mice. Data are expressed as mean ± SEM. *p < 0.05; unpaired two-tailed student t test. 
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mammary tumor at 15 weeks of age, when 90% of the 
control littermates were still tumor-free, although all the 
animals eventually developed tumors within 20 weeks 
of age. Moreover, as shown in Figure 1c, mice 
supplemented with resveratrol suffered from a higher 
number of tumor masses than controls, with an average 
of 9 tumors/mouse and 6 tumors/mouse, respectively 
(p=0.044). The enhanced proliferation rate triggered by 
resveratrol correlates with an increased expression of 
proliferating cell nuclear antigen (PCNA) in tumors 
from treated animals as demonstrated by immuno-
histochemical (IHC) analysis (Figure 1d).  
 
Resveratrol triggers Δ16HER2 over-expression and 
ERα down-regulation  
 
To investigate the molecular mechanisms underlying the 
boosted cancer growth induced by resveratrol, ERα and 
Δ16HER2 protein levels were analyzed by western blot 
in tumors explanted from resveratrol-treated and control 
mice. We found that in vivo administration of resveratrol  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
caused a dramatic drop in the ERα expression (Figure 2a, 
p<0.05) and a concomitant increase in Δ16HER2 protein 
level (Figure 2b, p<0.05) in tumors. Confocal micro-
scopy analysis confirmed the significant higher 
abundance of Δ16HER2 in both primary tumors (Figure 
2c) and lung metastatic lesions (Figure 2d, p<0.05) from 
resveratrol-treated mice compared to controls. These data 
suggest that the effect of resveratrol on Δ16HER2 protein 
accumulation is similar in primary tumors and 
metastases, although resveratrol supplementation did not 
seem to influence the number of lung metastases (3 out of 
6 mice were found with pulmonary metastases in the ve-
hicle group, 4 out of 7 mice in resveratrol-group, Fig. S1). 
 
Resveratrol in vitro treatment of Δ16HER2+/ERα+ 
breast cancer cell lines (luminal B subtype) 
recapitulates the in vivo outcomes 
 
To confirm the pro-tumor effect of resveratrol in human 
Δ16HER2+/ERα+ breast cancer, we tested resveratrol 
in vitro on human BT474 and murine CAM6 cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Resveratrol triggers HER2 over-expression and ERα down-regulation in luminal B breast cancer cell
lines. (a) CAM6 and (b) BT474 cells were incubated for 24 hours in the presence of vehicle or increasing concentrations of
resveratrol and cell viability was determined by MTT assay. Results (including vehicle group treated with 0.02 % DMSO) are
expressed as percentage (%) of cell viability relative to untreated controls. Columns, mean of three separate experiments
wherein each treatment was repeated in 16 wells; bars, SE. **p ≤ 0.01, ***p ≤ 0.001, one-way ANOVA followed by Bonferroni's
multiple comparison test. Representative western blot analysis of HER2, ERα and β-actin (loading control) in murine CAM6 cells
(c) or human BT474 cells (d), treated with resveratrol or 17β-estradiol or vehicle for 24 hours (upper panel), and relative
densitometry quantification (lower panel). The significance was determined by one-way ANOVA (*p < 0.05, **p ≤ 0.01). 
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CAM6 cells have been established from Δ16HER2 mice 
and can be considered the in vitro counterpart of 
Δ16HER2 mammary tumors [17]. After 24 hours’ 
incubation, despite high resveratrol concentrations 
resulted in reduced cell viability, low-range resveratrol 
concentrations (20-30 µM) promoted cell proliferation 
of both CAM6 and BT474 cells (Figure 3a and 3b), 
mimicking the in vivo resveratrol effect. Consistently, 
western blot analysis revealed that treatment with 40 
µM resveratrol for 24 hours induced HER2 up-
regulation and a concomitant ERα down-regulation in 
both CAM6 and BT474 cells, recapitulating the 
molecular events observed inside Δ16HER2 tumors 
(Figure 3c and 3d). Since 10 nM 17β-estradiol treatment 
only partially reproduced the resveratrol effect in 
CAM6 cells, inducing reduction of ERα without enhan- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cing HER2 protein levels, we suppose that resveratrol 
exerts a more complex action on Δ16HER2+ cancer 
cells than the mere estrogen-like effect. 
 
Resveratrol causes Δ16HER2 protein accumulation 
by partial inhibition of proteasome activity 
 
To evaluate whether the resveratrol-induced Δ16HER2 
over-expression was due to transcriptional or post-
transcriptional mechanisms, Δ16HER2 mRNA levels 
were analyzed by qRT-PCR in mammary tumors from 
resveratrol-treated and control mice. Despite the 
significantly higher level of Δ16HER2 protein detected 
in resveratrol-treated tumors in comparison with 
controls (Figure 2b and 2c), no differences in Δ16HER2 
mRNA levels were found between the two experimental 
groups (Figure 4a and 4b). By contrast, the activity of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Resveratrol inhibits the chymotrypsin-like activity of 20S proteasome and resulted in an increased
accumulation of protein-ubiquitin conjugates. Δ16HER2 and β-actin (internal control) mRNA levels were measured by semi-
quantitative RT-PCR (a) and qRT-PCR (b) analyses in spontaneous mammary tumors from Δ16HER2 mice supplemented or not with
resveratrol. (c) The chymotrypsin-like activity of the 20S proteasome was measured in tumor samples, from Δ16HER2 mice treated or
not with resveratrol, as described in Materials and Methods, and expressed as fluorimetric units (FU) min-1 mg-1. The significance was
determined by unpaired two-tailed student t test, *p < 0.05. (d) Western blot analysis of 20S proteasome subunit content (upper panel)
and ubiquitin-protein conjugates and free ubiquitin levels (lower panel) in tumor samples from Δ16HER2 mice treated or not with
resveratrol. β-actin was used as loading control. (e) Representative western blot analysis of p53 and β-actin (loading control) in
spontaneous mammary tumors from Δ16HER2 mice, supplemented or not with resveratrol, and (f) relative densitometric quantification
from three independent experiments. The significance was determined by unpaired two-tailed student t test, *p < 0.05.  
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the 20S proteasome, which is responsible for the 
degradation of the bulk of the cellular proteins, was 
significantly affected by in vivo supplementation of 
resveratrol, as determined by the 20S chymotrypsin-like 
activity assay in tumor extracts (Figure 4c). 
Noteworthy, no difference was found in the cellular 
levels of the 20S subunits, suggesting that resveratrol 
may exert a direct inhibitory effect on the proteasome  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
enzymatic activity (Figure 4d, upper panel). In 
agreement with a partial inhibition of the proteasome, 
tumor masses from resveratrol-treated mice displayed a 
higher extent of ubiquitin-conjugated proteins with 
respect to those obtained from mice receiving placebo 
(Figure 4d, lower panel). Consistently, western blot 
analysis also revealed a significant increase in the levels 
of p53 protein in mammary tumors from resveratrol- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Increased HER2 level induced by resveratrol results in a preferential activation of
mTORC1/p70S6K pathway. Representative western blot analysis of HER2 and HER3 downstream signaling pathways
in spontaneous mammary tumors from Δ16HER2 mice, treated or not with resveratrol (left panels), and densitometry
quantification from three independent experiments (right panels). (a) PI3K/AKT and (b) mTOR signaling pathways were
analyzed. β-actin was used as loading control. The significance was determined by t-test (*p < 0.05; **p ≤ 0.01; ***p ≤
0.001). (c) Resveratrol promotes the direct coupling of Δ16HER2 to HER3 kinase in HER2+/ERα+ breast cancer. Δ16HER2
kinase co-immunoprecipitates with pHER3. Proteins were immunoprecipitated with anti-HER2 antibody and then
probed by western blot for pHER3. Input represents 10% of the co-immunoprecipitation protein amount (30 μg). 
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receiving mice in comparison with controls (Figure 4e 
and 4f, p<0.05), giving further evidence of resveratrol-
mediated proteasome inhibition. Noteworthy, such p53 
augmentation inside tumors of resveratrol group did not 
trigger a concomitant up-regulation in the apoptotic cell 
death, as indicated by IHC analysis of cleaved caspase 3 
(Figure S2). Moreover, the ability of resveratrol to 
inhibit in a concentration-dependent manner the activity 
of the proteasome was confirmed in both BT474 and 
CAM6 cell extracts (Figure S3).  
 
Δ16HER2 accumulation induced by resveratrol 
results in a preferential activation of mTORC1/ 
p70S6K/4EBP1 pathway 
 
To identify the signaling cascades beneath the 
resveratrol-induced Δ16HER2 accumulation, the main 
oncogenic pathways known to be involved in breast 
carcinogenesis were analyzed by western blot. As 
shown in Figure 5a, despite tumors from resveratrol-
treated mice expressed significantly higher Δ16HER2 
levels than vehicle counterparts, no relevant differences 
were detected in its phosphorylation status. Noteworthy, 
phosphorylated HER3 levels were significantly higher 
in tumor extracts from resveratrol-treated animals 
(Figure 5a). Consistent with the over-expression of 
Δ16HER2 and increased HER3 phosphorylation, 
tumors displayed high levels of Δ16HER2-HER3 
heterodimer upon resveratrol treatment, as measured by 
co-immunoprecipitation assay (Figure 5c). This result 
suggests that resveratrol-induced accumulation of 
Δ16HER2 leads to Δ16HER2/HER3 heterodimer 
formation and consequently to HER3 transactivation. It 
is known that HER2/HER3 heterodimers are powerful 
oncogenic units, in part because phospho-HER3 boosts 
PI3K-AKT-mTOR signaling pathway [18].  
 
Consistently, we found that resveratrol-induced 
Δ16HER2/HER3 heterodimerization caused a 
concomitant increase in the levels of PI3K p85 and 
PI3K p110α (PI3K-p85, p<0.01 and PI3K-p110α, 
p<0.05) and the up-regulation of the mammalian target 
of rapamycin complex 1 (mTORC1). The mTOR 
Ser/Thr kinase is the catalytic component of two 
structurally and functionally distinct signaling 
complexes. The rictor-containing mTORC2 regulates 
the actin cytoskeleton and activates Akt [19]. The 
raptor-containing mTORC1 regulates cell growth and 
nutrient signaling [20]. In particular, mTORC1 
phosphorylates p70 S6 kinase (S6K) and eukaryotic 
initiation factor 4E binding protein 1 (4EBP1), thereby 
regulating translation of proteins that are critical for 
progression from G1 into S phase [21]. Therefore, we 
examined levels of phospho-4EBP1 and phospho-S6K 
as readouts of mTORC1 activity. As shown in Figure 
5b, resveratrol significantly increased both phospho-
4EBP1 (p<0.01) and phospho-S6K levels (p<0.05) 
relative to vehicle. The phosphorylation of these two 
par excellence mTORC1 downstream effectors 
positively correlated with the level of mTOR Ser(P)-
2481, while lower rictor and mTOR Ser(P)-2448 
pointed toward inhibition of mTORC2. Interestingly, 
although resveratrol supplementation promoted the 
inhibiting phoshorylation of PTEN (pPTEN 
ser380/thr382/383) [22], no differences in terms of 
AKT activation (pAKT) were observed between 
resveratrol and control groups: this may be due to 
feedback loops that compensate PI3K-mediated AKT 
activation. Interestingly, other pathways known to be 
activated downstream Δ16HER2, such as the 
Δ16HER2/Src/STAT3 axis, did not vary significantly 
between the two experimental groups (Figure S4). It is 
worth to note that the levels of unphosphorylated 
proteins other than HER2, like mTOR (Figure 5b), Src 
and Erk1,2 (Figure S4) increased in tumor extracts from 
resveratrol group. This observation is consistent with 
the ubiquitin-proteasome system (UPS)-dependent 
degradation of these proteins [23-26] and supports our 
evidence about resveratrol acting as proteasome 
inhibitor.  
 
DISCUSSION 
 
The need for safe and low-toxic preventive and 
therapeutic strategies against cancer is still unmet. In 
this scenario phytoestrogens like resveratrol have 
received growing attention as valuable chemo-
preventive tools. Contrarily to previously published 
results [12], describing an antitumor effect of 
resveratrol in a HER2+/ERα- breast cancer 
experimental model, here we have found that 
resveratrol, given at the same reported dose, regimen 
and administration way, did not prevent nor delay tumor 
onset; instead, significantly accelerated cancer 
development in Δ16HER2 females that spontaneously 
develop HER2+/ERα+ mammary carcinomas. 
 
In Δ16HER2 mice, resveratrol intake not only 
anticipated the tumor onset, but significantly augmented 
tumor multiplicity, promoting the growth of a higher 
number of tumor masses per mouse. Moreover, 
consistently with its pro-proliferative effect, we provide 
evidence that resveratrol treatment induced a strong 
increase in Δ16HER2 expression, associated with a 
significant reduction of ERα protein level. In contrast to 
the observation by Provinciali et al., resveratrol did not 
affect Δ16HER2 mRNA levels, suggesting that 
Δ16HER2 protein accumulation was the consequence of 
a reduced degradation rather than an increased 
transcription. Indeed, it has been demonstrated that 
resveratrol can act as a potent proteasome inhibitor [27, 
28]. In our experimental settings, resveratrol treatment 
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partially inhibited the chymotrypsin-like proteasome 
activity, which may elicit the observed accumulation of 
Δ16HER2 protein in mammary tumors, that in turn 
fuels cancer growth. Noteworthy, the same result was 
obtained in vitro using murine and human luminal B 
breast cancer cell lines (CAM6 and BT474 cells, 
respectively). Indeed, adding resveratrol to cell-free 
extracts of CAM6 and BT474 resulted in a 
concentration-dependent proteasome inhibition. On the 
whole, the in vivo and in vitro evidence we gathered 
suggests that resveratrol can act as a proteasome 
inhibitor as Qureshi et al. claimed [26]. Nonetheless, we 
cannot exclude that additional effects of resveratrol on 
signaling cascades might eventually mediate an indirect 
proteasome inhibition as well. Anyhow, the ability of 
resveratrol to inhibit the proteasome can be considered a 
double-edged sword. On one side, resveratrol has been 
reported to exert anti-inflammatory effects partially by 
counteracting the proteasome-mediated activation of 
NF-κB, thereby suppressing activation of pro-
inflammatory cytokines and iNOS genes [26]. Since 
inflammation is a hallmark of neurodegenerative 
disorders and aging [29, 30], proteasome inhibition 
triggered by resveratrol might provide additional insights 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
into its anti-aging properties as well. On the other side, 
as our evidence has demonstrated, proteasome im-
pairment and the consequent HER2 accumulation can 
promote breast cancer development. Strikingly, this 
resveratrol-induced Δ16HER2 increase was associated 
with a concomitant ERα diminution. ERα is of critical 
importance in mammary cancer initiation and 
progression, having become an ideal target for anti-
cancer therapies. However, expression of ERα in tumors 
is dynamic and can change during the course of tumor 
progression and following therapy [31, 32]. Loss of 
ERα represents a crucial mechanism for the acquisition 
of endocrine resistance [33-35]. Several clinical and 
preclinical studies have confirmed the existence of a 
remarkable crosstalk between HER2 and ERα that 
usually leads them to be inversely expressed inside 
breast cancer. Strikingly, such bidirectional fluctuations 
dictate the responsiveness to HER2- and/or ER-targeted 
therapies [36-38]. Accordingly, it has been shown that 
resistant breast cancer cells have higher HER2 
expression than endocrine therapy-sensitive cells [39]. 
Our data perfectly fit in this scenario, suggesting that 
resveratrol treatment mirrors endocrine resistance 
acquirement, triggering HER2 up-regulation and ERα  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Proposed resveratrol’s mechanism of action in a luminal B breast cancer model. Our data show that
resveratrol down-regulates ERα and lowers the chymotrypsin-like activity of the 20S proteasome in HER2+/ERα+ breast cancer,
leading to an increased accumulation of Δ16HER2, which efficiently couples to HER3 and activates the PI3K-AKT-mTOR
pathway. In particular, Δ16HER2/HER3 heterodimers trigger the mTORC1/p70S6K/4EBP1 signaling axis inducing an up-
regulation of protein synthesis and cell growth. On the other hand, resveratrol inhibits mTORC2 and promotes phosphorylation
of PTEN, reducing its catalytic activity, thereby enhancing PI3K-mediated AKT activation, while feedback loops compensate it.
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repression. Our results also support the hypothesis that 
resveratrol may exert its anti-ERα action by impairing 
proteasome-mediated ERα activation. Interestingly, 
UPS has been described as necessary for a correct 
activation of ERα [40] and some proteasome inhibitors 
have been shown to repress ERα gene expression [41, 
42]. Moreover, a recently published work has proposed 
that mTORC1 inhibition activates the Ubiquitin/Protea- 
some System (UPS) and autophagy [43], thus sustaining 
an inverse correlation between mTOR signaling and 
proteasome activity. Consistently, we have reported the 
resveratrol-induced over-expression of Δ16HER2 
eventually results in the activation of mTORC1/p70S6K/ 
p4EBP1 axis. This observation recapitulates a relevant 
molecular pathway implicated in endocrine resistance 
development [44] and may explain why the 
combination of resveratrol and mTORC1 inhibitors 
have stood out as more effective anti-tumor therapy 
than single-agent approaches [45, 46]. 
 
Interestingly, despite the claimed anti-aging effect of 
resveratrol, longevity studies have demonstrated that 
combination of rapamycin and resveratrol was not able 
to prolong the overall mice survival as mTOR inhibition 
does [47]. This aspect further strengthens the 
connection between resveratrol and mTOR pathway and 
suggests that our data might be extended to a broader 
context such as aging-related dysfunctions exhibiting a 
preferential activation of mTORC1 pathway [48]. 
 
In conclusion, this study provides evidence that the 
effects of resveratrol treatment depend on intrinsic 
molecular cancer properties, exerting a tumor-
promoting effect in luminal B breast cancer subtype by 
acting as proteasome inhibitor and inducing a multi-
target molecular rearrangement (Figure 6). 
 
MATERIALS AND METHODS 
 
Animals 
 
Δ16HER2 female mice were housed under controlled 
temperature (20 °C) and circadian cycle (12 hours 
light/12 hours dark) in the animal facility of University of 
Camerino. The animals were fed on chow diet and tap 
water ad libitum. 
 
Cell culture 
 
CAM6 cells, a Δ16HER2-expressing epithelial tumor cell 
line derived from a mammary carcinoma spontaneously 
arisen in a Δ16HER2 female [17] and BT474 cell line 
were maintained in DMEM (Lonza) supplemented with 
10% FBS (Gibco, Life Technologies) and 1% penicillin-
streptomycin (Gibco, Life Technologies). Cells were 
cultured at 37 °C under humidified atmosphere with 5% 
CO2.  
 
Resveratrol treatment 
 
8 week-old Δ16HER2 female mice were randomly 
divided into two experimental groups (n=9 each). One 
group underwent resveratrol treatment and the other 
was given control vehicle, as previously reported [12]. 
Briefly, resveratrol (Sigma) was dissolved in methanol 
to be then diluted in tap water to a final concentration of 
1mg/l. Being the daily water intake of about 4 
ml/mouse, 4 μg resveratrol/mouse was the daily dose 
assumed. The control mice were supplemented with 
0.02% methanol in tap water (vehicle). Both vehicle- 
and resveratrol-containing water was renewed twice a 
week. During the treatment (from 8-weeks to 23-weeks 
of age), mice were weekly monitored for mammary 
tumor development by palpation and growing masses 
greater than 2 mm in mean diameter were regarded as 
tumors. Two perpendicular diameters (a and b) were 
measured on each tumor using caliper and volumes 
were calculated by the V = π/6[(a+b)/2]3 formula. All 
animal experiments were carried out in accordance with 
the U.K. Animals (Scientific Procedures) Act, 1986 and 
associated guidelines, EU Directive 2010/63/EU for 
animal experiments, and were approved by the Ethic 
Committee on Animal Use of the University of 
Camerino (protocol number 14/2012). At the end of 
experiment mice were euthanized and tumors and lungs 
samples were collected for subsequent analyses. For the 
in vitro experiments resveratrol was dissolved in DMSO 
(Sigma) and then diluted in complete DMEM to usage 
concentrations (10-100 μM). 17β-estradiol (Calbiochem) 
was used as control estrogen treatment (stock solution 40 
mM in 100% ethanol and diluted in complete DMEM to 
10 nM), as previously described [41]. Cells were treated 
for 24 hours with resveratrol/17β-estradiol- or vehicle-
containing medium (0.02% DMSO).  
 
Cell viability assay  
 
Resveratrol effect on cell viability was evaluated by 
seeding 4x104 cells/well (CAM6 cells) or 2.5x104 
cells/well (BT474 cells) in 96-well plates in complete 
DMEM. The day after, fresh medium containing 
appropriate resveratrol concentrations was added. Cell 
viability was determined via MTT assay. MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
was purchased from Sigma Aldrich (St. Louis, MO). 
 
Immunohistochemistry (IHC) and confocal 
microscopy analyses 
 
Tumors and lungs harvested from mice were fixed in 
4% paraformaldehyde solution for 24-48 hours at room 
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temperature and then embedded in paraffin. Paraffin-
embedded sections were stained with hematoxylin and 
eosin or immunostained with anti-mouse PCNA 
monoclonal antibody (Dako) or with anti-cleaved 
caspase-3 monoclonal antibody (MAB835, R&D 
Systems, Milan, Italy). After washing, they were 
overlaid with appropriate secondary antibody. 
Immunostaining was developed with Vulcan Fast Red 
(Biocare) alkaline phosphatase method. The number of 
cleaved caspase-3 positive cells was evaluated on 
digital images of controls and resveratrol tumors (10 per 
group, 5 x 400 microscopic fields per tumor). As it 
regards confocal microscopy analysis, after incubation 
in blocking buffer for 20 minutes, tissue sections were 
incubated for 1 hour at 37 °C with anti-NEU polyclonal 
antibody (diluted 1:50, Santa Cruz). Nuclei staining was 
performed using DRAQ5 probe (Life technologies) 
according to the manufacturer instructions. After 
washing, the coverslips were incubated with Alexa 488-
conjugated goat anti-rabbit secondary antibody (diluted 
1:100, Life technologies) for 1 hour at 37 °C. Slides 
were viewed using a Zeiss LSM 510 Meta Confocal 
Microscope. Quantitative measures were obtained via 
ImageJ software. 
 
Protein extraction and western blot analysis 
 
Tumors and treated cells were homogenized in RIPA 
buffer (0.1% SDS, 1% NP40, 0.5% CHAPS) 
supplemented with protease inhibitors aprotinin, sodium 
orthovanadate and phenylmehylsulfonyl fluoride 
(Sigma-Aldrich, St. Louis, MO). After 30 minutes’ 
incubation on ice, whole tumor lysates were centrifuged 
at 14000 rpm, 4 °C, for 20 minutes. The supernatant 
was collected and proteins were quantified via Bradford 
assay (Bio-Rad). For western blot analysis equal 
amounts of protein lysates were separated onto 
Criterion™ TGX™ precast gels (Bio-Rad) and 
transferred to a polyvinylidene difluoride (PVDF) 
membrane (Millipore) using Criterion™ Blotter (Bio-
Rad). After blocking in 5% BSA-TBS-T for 1 hour, 
membranes were incubated with primary antibodies at 4 
°C overnight. Secondary antibody-binding was 
performed at room temperature for 1 hour. After TBS-T 
washing, protein bands were incubated with LiteAblot 
PLUS reagent (Euroclone) and detected via 
ChemiDoc™ XRS+ System (Bio-Rad). Densitometry 
analysis was performed through ImageJ software. 
Detailed information about the used antibodies is 
available in Table S1, Supplementary Information. 
 
Co-immunoprecipitation 
 
300 μg of tumor cell lysates were incubated overnight 
with anti-NEU polyclonal antibody (diluted 1:200, 
Santa Cruz) at 4 °C. After washing in RIPA buffer at 
2500 g, 4 °C for 5 minutes, 200 μl of protein G 
Sepharose 4 Fast Flow beads (GE Healthcare) were 
added to each tube. Incubation was performed for 4 
hours at 4 °C under gentle rocking. Following washing 
procedure, the samples were boiled in Laemli loading 
buffer for 5 minutes: the collected supernatants under-
went western blot procedure.  
 
mRNA extraction, RT-PCR and qRT-PCR 
 
Total RNA was extracted from liquid nitrogen cryo-
preserved tumors via TRIzol® reagent (Life 
Technologies) following the manufacturer instructions. 
RNA was quantified by measuring 260 nm absorbance 
via NanoDrop 1000 spectrophotometer (Thermo 
Scientific). RNA purity was considered good with 
A260/A280 ratio ≥ 2.0 and A260/A230 ratio ≥ 1.7. 
RNA (2 µg/tube) was reverse-transcribed using the 
High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Semi-quantitative RT-PCR was 
performed using Perfect Taq DNA polymerase (5-
PRIME) and Eppendorf thermal Cycler. SYBR Premix 
Ex Taq (Tli RNaseH Plus) reagent (Takara) was used 
for qRT-PCR analysis. β-actin was taken as 
housekeeping gene and standard curves for target genes 
and β-actin were included to evaluate reaction 
efficiency. Experiments were performed in triplicates. A 
2-steps amplification program was carried out on Bio-
Rad iCycler Thermal Cycler with iQ5 Multicolor Real-
Time PCR Detection System. Primers used: Δ16HER2 
forward: 5’-CACCCACTCCCCTCTGAC-3’; Δ16HER2 
 reverse: 5’-GCTCCACCAGCTCCGTTTCCTG-3’; β-
actin forward: 5’-CAAGGCCAACCGCGAGAAGAT-
3’; β-actin reverse: 5’-GTCCCGGCCAGCCAGGTCC 
AG-3’. 
 
Proteasome activity 
 
The chymotrypsin-like activity of the 20S proteasome 
was assayed on tumor and cell extracts using the 
fluorogenic substrate N-Succinyl-Leu-Leu-Val-Tyr-7-
Amido-4-Methylcoumarin (sLLVY-NH-Mec, Sigma-
Aldrich). Briefly, tissues/cells were homogenized on ice 
via a Potter-Elvehjem apparatus in a buffer consisting of 
50 mM HEPES/KOH pH 7.8, 1 mM Dithiothreitol and 
0.25 M Sucrose. The lysates were then cleared by 
centrifugation at 12.000 rpm for 10 minutes in a 
refrigerated Eppendorf centrifuge. Twenty and 40 µg of 
total proteins from each tissue sample were incubated at 
37°C in 100 mM HEPES/KOH buffer, pH 7.8, 5 mM 
MgCl2 and 10 mM KCl. Cell extracts (10 µg) were 
preincubated for 30 min at 37°C in the same buffer with 
the addition of different concentrations of resveratrol or 
with only the vehicle (DMSO). In both cases the 
reaction was initiated by addition of the fluorigenic 
substrate to a final concentration of 0.2 mM. The 
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breakdown of the peptide was monitored for 30/45 min 
using a fluorescence microplate reader (FLUOstar 
OPTIMA, BMG Labtech GmbH, Offenburg, Germany) 
with an excitation wavelength of 355 nm and an 
emission wavelength of 460 nm. Proteasome activity in 
each sample, expressed as fluorimetric units min-1 mg-1, 
was calculated by submitting data to linear regression 
analysis (R2 >0.99). 
 
Statistical analysis 
 
Quantitative data are presented as means ± SEM from 
three independent experiments. The significance of 
differences was evaluated with two-tailed Students t-
test, or one-way ANOVA followed by Bonferroni post-
test. Statistical analysis was carried out with GraphPad 
Prism5. 
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